Background: The goal of clinical microbiology is to identify the cause of infection, aiding rapid treatment initiation or altering empirically chosen anti-microbial regimens. Automation and molecular techniques have brought about a revolution in the clinical laboratory, ensuring ever faster and more accurate diagnoses. In the last few years however, there have been a number of developments that radically alter the way that microbiology and other diagnostic laboratories are advancing. In particular, clinical microbiology will have the opportunity to intervene at the public health level as well as at the individual patient.
Introduction
In line with healthcare goals, the methods and techniques used in diagnostic microbiology to identify causative organisms should be efficient and cost-effective, utilizing where appropriate the latest technologies. In turn the identification of the causative organisms should result in rapid treatment initiation, or alternatively, adjustment of initial empiric treatment.
Several factors have an impact on the decision over which technologies to incorporate into laboratory workflows. First, the level of 'identification' that is required for clinical management has to be considered. This can be quite complex. In some cases the identification of a pathogen to a genus or species level is a sufficient surrogate for intrinsic drug resistance and, conversely, can be used to select drugs to which the pathogen in question will respond. 1 Identification of a virus on the other hand, may mean that empiric antibiotic treatment can be halted. More often nowadays however, where bacteria and fungi are identified as the causative agents and in light of the rising levels of antibiotic resistance, drugsusceptibility testing is becoming the norm for an increasing number of pathogens. 2 Additionally, further steps to identify virulence determinants such as toxins or antigens may also be required for treatment of some species. 1, 3 Secondly, the frequency with which pathogens are isolated impacts on whether or not they are routinely screened for and hence the assay or technology used. In this context, the costs for reagents, equipment and staff to run tests associated with rare pathogens are often prohibitive for local laboratories, unless samples are batched extensively. 1, 2, 4 Therefore, such services are usually offered by reference laboratories, which can introduce long delays. 1, 2 Lastly, the overall structure of local and national service delivery affects methodologies and technologies used. Diagnostic services in the UK are currently undergoing a process of rationalization, which involves a shift towards laboratory amalgamation, adoption of 24/7 working patterns and greater automation in order to reduce costs. 1, 5 This review will explore technologies that are already or are expected to be important in this on-going transition because they simplify or accelerate the complex workflows that are required for pathogen identification.
Array systems
With the scientific evolution from monoplex to multiplex real-time PCR assays, there has been a recent transition revisiting monoplex assays but utilizing them as 'simultaneous singleplex' for multiple pathogen detection using the array technology. The pathogens that can be detected simultaneously cover the full spectrum-bacteria, RNA viruses, DNA viruses, atypicals, parasites and fungi and can allow for a syndromic approach to diagnosis, as opposed to the more customary pathogen-focused PCR technologies. One format, the TaqMan low-density array (TLDA, Life Technologies, Carlsbad, CA , USA) uses microfluidic cards in which lyophilized primers and probes for each assay are pre-loaded and dried onto wells. The usual configuration of this card is 8 loading ports (samples) with 48 connected wells per sample (384 wells in total). A single target is tested in each of the wells. Nucleic acid extract is added to mastermix and this (100 µl total) is transferred to the loading port. Once each of the eight samples has been loaded, the plate is centrifuged allowing channelling of the mixture to each well; the plate is then sealed and loaded into the analyser for RT-PCR, where the amplification and detection can take place in less than an hour.
The array technology permits a flexible approach; new targets and updated primers/probes can be added or altered without the need to re-validate the entire assay (as would be required in a multiplex assay). Although only a small number of samples are run on each card, when compared with individual PCR assays, throughput is greatly increased. Turnaround time is reduced especially when compared with bacterial culture. There is less handling time and minimal training is necessary (as opposed to the experience and expertise required for bacterial and parasite identification). Data output is as a single file allowing for ease of interpretation. Lyophilization of the primers and probes ensures that the plate has a long shelf-life of up to 2 years when refrigerated.
Plates can be designed with specific syndromes in mind-for example enteric, sepsis and jaundice/ transplant plates. There is also the possibility for inclusion of antibiotic/drug-resistance gene detection, e.g. carbapenemases/oseltamivir resistance. Arrays can be designed to respond to outbreaks, provide surveillance and play a pivotal role in public health protection. Studies trialling these arrays have reported improved case finding, with pathogens identified that were not specifically requested by clinicians. The plates can also be 'personalized' allowing investigators to harness in-house PCR assays to detect their pathogens of choice. Individual assays have to work optimally at one annealing temperature and these assays may have to be strengthened to maintain sensitivity. Multiple pathogens may be detected in a sample and it is then reliant on clinical judgement to distinguish between carriage and disease, although the cycle threshold 'Ct' value for each pathogen (a measure of the amount of pathogen within the sample) can aid interpretation.
Kodani et al. 6 described the first application of TLDA for infectious disease diagnostics to detect 21 respiratory pathogen targets (13 viral and 8 bacterial). TLDA cards exhibited good overall sensitivity and specificity of 89 and 98%, respectively, when compared with individual real-time PCR assays but had relatively low sensitivities (≤75%) for M. pneumoniae, C. pneumoniae and B. pertussis target II. Weinberg et al. 7 found the assay to lack sensitivity for adenovirus and parainfluenza −1 and −2 (54, 56 and 75%, respectively). The diagnostic performance for the array assays displaying sensitivities ≤75% clearly need to be improved prior to implementation of this methodology as a routine screening test. Certainly, the difference in sensitivity observed for adenovirus and parainfluenza of 1 and 2 by Weinberg et al. could reflect the potential bias introduced by using a significantly reduced annealing/extension temperature (55°C) for the individual RT-qPCR assays compared with that used for the same assays (60°C) on the array card. Judging by the exquisite sensitivities obtained for the majority of assays on the array, improvements are possible, whereby only the crème de la crème of assays should be allowed to populate the eventual diagnostic array card.
The array technology also demonstrates the potential to be utilized in near-patient testing. The FilmArray technology (BioFire Diagnostics, Inc., Salt Lake City, UT) takes an unprocessed clinical specimen through to amplicon melt curve analysis in a single pouch format in 1 h in a closed system. Following a first stage, multiplex PCR, the sample is transferred into wells of 1 µl volume each for nested PCR with individual primers for each target. The FilmArray Respiratory Panel can identify 21 viral and bacterial respiratory pathogens, with multiple targets for some and has the potential to detect >100 targets simultaneously. The minimal human intervention, rapid result and single sample processing make an ideal format for near-patient testingalthough single sample testing limits its capacity for high-throughput testing. The FilmArray was found to have an overall sensitivity of 89.4% and a specificity of 99.6% when compared with laboratorydeveloped real-time PCR assays, 8 although it lacks sensitivity in detecting certain adenovirus serotypes. 8, 9 The FilmArray technology also has an FDAcleared blood culture identification panel and a gastrointestinal panel in development.
Liquid bead arrays, developed using the principles of flow cytometry, are another recent addition to the array spectrum. An example of this is xTAG technology developed by Luminex Molecular Diagnostics (Austin, TX, USA). In this system, polystyrene microspheres, microns in diameter are internally dyed with fluorophores, creating a unique set of beads, which are pre-coupled with TAG sequences. Multiplex PCR is performed with target-specific primer pairs, one of which is extended at the 5′ end with a TAG sequence (unique to each target) and the other with a 5′ Biotin label. Following amplification, a process of 'array sorting' takes place whereby the TAG sequence on a bead becomes hybridized to its complementary TAG sequence on the opposite strand (of the amplicon) extended by the biotin labelled primer. A stream of suspended microspheres then passes through a laser detector which measures the fluorescence of the bead as well as the streptavidin phycoerythrin bound to the biotin. Detection of both together identifies amplification of the specified pathogen (containing the unique TAG) in the specimen, a positive PCR result. More than 100 microsphere sets with unique spectral signatures have been created allowing multiplexing of a large number of targets. This technology has been used to create respiratory panels (xTAG RVP Fast and RVPv1), which include viral targets only, and a gastrointestinal panel (xTAG GPP), which can detect a variety of bacterial, viral and parasite intestinal pathogens. Overall, the xTAG GPP has shown good sensitivity for most targets, although it lacks sensitivity for certain adenovirus serotypes (non 40/41). 10 The xTAG respiratory panels demonstrate good sensitivity and specificity but have the disadvantages of long hands-on time, lengthy instrument time, limitation to viral targets and of not being closed systems, which increases the risk of laboratory contamination.
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Next-generation sequencing
In 1995, the first bacterial genome to be sequenced cost 31 pence per finished base pair, 11 which corresponds to ∼£950 000 for the entire genome taking inflation into consideration. In contrast, a bacterial genome can now be sequenced for <£100 in consumables in ∼24 h. 12 In fact, bacterial whole-genome sequencing (WGS) is now possible directly from a single colony on a primary isolation plate without the need for subculture or a complicated extraction method. 13 A thorough discussion of the technical details of the various rapid desktop sequencers such as the Illumina MiSeq or Ion Torrent PGM (Life Technologies) can be found elsewhere. 14, 15 Instead, we will highlight the areas in which these technologies are already beginning to make a clinical impact. 1, 3 First, it is important to appreciate that the aforementioned prices for a bacterial genome can only be achieved if the DNA is pure. Unbiased metagenomic studies directly from clinical samples remain prohibitively expensive in most clinical scenarios and are less sensitive than traditional detection/identification methods. 1, 16 Therefore, a primary culture, either in liquid or on solid media, will remain routine in diagnostic bacteriology in the foreseeable future. 1, 17 Secondly, even starting from a primary isolation plate, WGS is not cost-effective in most cases given that MALDI-ToF (see below) and phenotypic drug-susceptibility testing are cheaper and/or faster.
1,2 WGS will, however, have a significant impact to address specialized questions where front-line identification or susceptibility testing methods fail. 1, 13 These tests are usually performed at the reference laboratory level, which reduces the cost per sample at the expense of the turn-around time. case the genome data would also provide the ultimate molecular resolution for outbreak investigations, i.e. depending on the rate of evolution relative to the rate of transmission, it would be possible to determine who infected whom. 1, 3, 18 This will allow unprecedented opportunities to interrupt transmission, 19 as first demonstrated in real-time in an MRSA outbreak investigation. 20 Several challenges remain before this potential of WGS can be realized. Despite the recent advances, 13 library preparation has to be simplified further in order to be suitable for lower grade technical staff. 1 Moreover, the duration and cost of WGS has to be reduced. The genetic basis of key antibiotics has to be investigated in greater detail, particularly for the Mycobacterium tuberculosis complex, where the time to diagnosis of highly drug-resistant cases could be reduced from weeks to days. 1, 17 Finally, the automation of data analysis represents the most imminent hurdle. This includes the development of standards to share sequence data to investigate regional and inter-national transmission of pathogens.
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A pragmatic approach to demonstrate the use of this technology has been the application of ultradeep sequencing (UDS) to sequence targeted amplicons such as the anti-viral target genes of HIV. Amplicons of 1500 bp or less can be sequenced at many 1000× depth and the ensuing data reported as the percentage of minority species present. This is especially important in RNA viruses such as HIV, which may exist within a patient as a number of quasi-species. Previously, anti-viral resistance was reported on a population basis, generating contigs from all the sequences present and reporting the consensus sequence and resistance mutations.
The advent of UDS has meant that it is now possible to determine the levels of resistance mutations present below the 15-20% cut-off shown to be the lower limit of detection for mutations in Sanger sequencing. 21, 22 There is a growing literature looking at the significance and clinical utility of minority resistance mutations in different settings, chiefly baseline resistance testing and cases of virologic failure. A large meta-analysis demonstrated clearly that in patients that were antiretroviral naïve, lowfrequency resistance mutations were associated with an increased risk of virologic failure. 23 Most studies looking at the utility of deep sequencing in the context of virologic failure to-date have been based on small patient cohorts and work is required to perform larger side-by-side comparisons with Sanger sequencing.
As with the other techniques described, UDS offers benefits above and beyond those of increase in amount and quality of data. Laboratories that perform in-house sequencing-based resistance testing have to train staff in contig generation and data analysis. These are time-consuming processes and require experienced staff. UDS can be automated and software is available that will take the complex data and analyse it, leaving the biomedical scientist to simply enter the final susceptibility report. On the horizon are assays for HIV tropism testing and the potential for WGS, allowing the sequences to be available for epidemiological purposes and drug discovery. Increasingly biotech companies are investing in this technology and the coming years should see a rise in the development and number of commercially available microbial sequencing systems.
In the near future UDS will become routine for HIV and other viruses (hepatitis C, hepatitis B, etc.) to be tested for resistance mutations, potentially improving treatment prediction, patient management and laboratory workflow. The latter improvement will depend on the workflow already in place in a clinical setting but should, in theory, provide benefits across many different routines.
Matrix-assisted laser desorption ionization: time of flight mass spectrometry
Matrix-assisted laser desorption ionization: time of flight mass spectrometry (MALDI-ToF MS) has been incorporated into the workflows of many diagnostic microbiology laboratories across the world since 2008 when the first commercially available systems were initially marketed. The conceptual approach of applying the organism to a steel plate (known as the 'target') and measuring and then analysing the complex mass spectral profile from cells and comparing that against a database of profiles from known organisms has remained relatively unchanged since the first experimental uses of the technology for organism identification and since the early databases of profiles from known organisms. 24 In the clinical diagnostic setting MALDI-ToF has proven attractive for clinical diagnostic laboratories due to its improved accuracy over existing identification techniques, 25, 26 time savings of ca. 1 working day for identification of an organism on an agar plate ( Fig. 1 ) and marginal cost savings in the region of 2-4E per identification compared with biochemical identification techniques. These benefits of MALDIToF in its most basic mode (the identification of organisms from solid agar media) has driven the rapid uptake of the commercially available platforms in clinical diagnostic laboratories. Timeliness in the identification of an infecting pathogen is one of the key factors that can impact positively on clinical outcome, particularly for highvalue samples such as blood cultures. Studies examining additional and extended uses of MALDI-ToF have focused on further shortening the time taken to gain a species identification result by targeting different points of the blood culture diagnostic workflow (Fig. 1) . Further to the 24 h time saving (compared with biochemical identification methods) for the identification from a fully grown agar culture taken from a positive blood culture, numerous laboratories have trialled the identification of organism from barely visible growth just 4 h after inoculation from the positive blood culture via MALDI-ToF (Fig. 1) . Even earlier identification results can also be gained direct from the liquid phase blood culture sample at the point that it flags as positive for microbial growth, saving ∼24 h for a standard MALDI-ToF identification result from a fully grown agar culture, 27 effectively yielding a result in around the same time period as a Gram stain result (Fig. 1) . Species identification at this point as opposed to a time equivalent Gram stain result, could better direct the choice of antimicrobial treatment in some cases, for example where Neiserria meningitidis is the agent responsible for sepsis. Key retrospective studies in this area have highlighted the potential for the earlier amendment of treatment regimens in 13.38% (21/157) of paediatric cases where species identification was gained direct from a positive blood culture via MALDI-ToF. Moreover in many other cases, the MALDI-TOF MS result was a helpful tool for infectious disease specialists as it confirmed suspected cases of contamination, especially in the paediatric population (15/40 RMIs, 37.50%), or suggested complementary diagnostic testing. 28 Earlier identification results have also been suggested to better inform the direction of clinical investigations into infection source(s), as well as public health and infection control measures. Whilst these approaches appear promising their true clinical value will not be understood until the results of currently ongoing case controlled 29 studies are known. In addition to species identifications MALDI-ToF has been shown to have the potential to impact the analysis of microbial samples in other clinical diagnostic workflows, including those relating to antimicrobial susceptibility. 30 The principles of these techniques are various and range from the detection of antimicrobial resistance determinants and mechanisms to a more general approach that determines or detects antimicrobial susceptibility. Whilst the direct detection of ions from beta-lactamase enzymes 31 has proven unreliable using whole-cell preparations from clinical isolates with a detection rate of only 70%, 28 MALDI-ToF may assist with less complex membrane protein samples where the loss of outer membrane porin expression is associated with carbapenem resistance in, e.g. K. pneumoniae. 32 Resistances that are contingent on mutations within genes can be detected with hybrid PCR/MALDI-ToF based protocols, shown by variant protocols that successfully detect the incorporation of SNPs in TEM-and SHV-beta-lactamases then extend a penicillinase phenotype to extended spectrum or ESBL activity. 33, 34 Enzymatic resistance mechanisms can also be investigated by detecting the antimicrobials and their modified or degraded derivatives. This has been shown with beta-lactamases (including carbapenemases) by incubating bacterial cultures with the antimicrobial for 1-4 h and analysing sample supernatants for β-lactam degradation via MALDI-TOF MS. 35, 36 Moreover, adding β-lactamase inhibitors to the incubation can further inform the effectiveness of that inhibitor for the sample. 37 Each of the three approaches above detects a mechanism of resistance. However, more diagnostically relevant is the detection or determination of an organism's susceptibility to an antimicrobial. For Candida albicans the discrimination of distinct MALDI-spectral-profile changes was possible between caspofungin susceptible and resistant isolates after 3 h incubation in the presence of a 'breakpoint' concentration of the drug. 38 An alternative and potentially more sensitive approach, which has been successfully correlated with bacterial (as opposed to fungal) drug susceptibilities, is the use of stable markers or isotopes, which cause mass shifts that can be assayed and used to differentiate actively growing from non-growing cultures in a given concentration of antimicrobial. 39 Whilst this latter technology is still new it does have the broadest and most clinically relevant range of specificity (i.e. it is essentially mechanism independent) and shows the most promise for clinical diagnostics. Whilst the rapid uptake of the MALDI-ToF technology has been driven by the characterization of bacteria already isolated the use of mass spectrometry will push into other areas of clinical diagnostics. These include antimicrobial resistance/susceptibility detection and also outbreak investigation and epidemiological typing, as has been observed with VRE. 40 In addition mass spectrometry seems likely to be relevant in the detection modality of clinical microbiology via systems such as the PLEX-ID system (which combines a PCR amplification screening step with an electrospray ionization mass spectrometry (ESI-MS) step to analyse the base composition of the products, providing identifiable signatures). Early evidence for the benefit of this technology in some clinically relevant scenarios 41 indicates that well controlled, systematic studies are now needed in this area also.
New technologies and the future
The new technologies described above have the potential to dramatically improve infectious disease detection and treatment. Some, such as MALDI-ToF described in the last section, already have a place in many of the more advanced diagnostic laboratories and their applications are constantly being refined. Others, such as the deep sequencing and array systems, are only just starting to be seen in diagnostic use and the next few years will determine exactly how they fit into the workflows or how workflows are adapted to include them. The often pragmatic decisions, which have to be made, have been discussed but it is clear that these are exciting times in clinical microbiology. The capacity to identify, quantify and rapidly test a huge range of micro-organisms is now available. This needs addressing, particularly where sequencing methodologies are involved to ensure good practice and standardization of approaches. Most importantly, however, these technologies will bring about a range of benefits to the patient, including speed and quality of diagnosis and improvements to anti-microbial testing. Ultimately with the advent of real-time sequencing of organisms the ability to perform real-time outbreak investigation and make a substantive impact on public health using clinical diagnostics will come of age.
